Gain-of-function mutations of the NOTCH1 gene are present in about 10% of NSCLC, and activation of Notch1 correlates with poor clinical outcomes in NSCLC patients [6]. The gene discussed is NOTCH1; the disease is non-small cell lung carcinoma.